Member Info for Hemo

Fantastic results, growth has exceeded Stifel forecasts so we are looking good for the full year.

I make the cash burn £1.4m so this should not unduly concern us as we move towards profitability.

Slightly concerned that Illumina timetable has slipped but hope it is just semantics.

This should fly now and I'm only 1p away from breakeven!

We should have a dual listing on Nasdaq then!

Probably not as simple as that or AR suggests!

Wrong again!

My wager is this week, probably Tuesday!

The share price is stuck again, let’s hope the update gives it some upward momentum!

When do we think it will be? 7th or 8th October?

Directors said in AGM Statement growth will be in line with expectations so according to Stifel should be 50%.

Did anyone go to the AGM by the way? We have had no reports back?

Yes, surely some new business has been won!

Surprised there is no newsflow at all, particularly with the AGM next week. Why is there nothing to say?!

Let’s hope they at least give an indication of H1 sales growth next week. I’m looking for at least 50%.

Do I detect some cynicism and realism emerging in your comments recently notaflipper?!

Yes they are not delivering and yes most of us are fed up. Communication is poor and delivery of contracts and momentum is even worse.

Yes looks like a buy to me

Truro

Are you Barry Hextall?! Your patronising responses are equally helpful.

I'm moving on from this debate now. The point is I shouldn't have to ask most of these questions, they should be in the announcements. I don't buy the commercial sensitivity nonsense, that definitely sounds like Barry.

TruroTrader

They're actually questions we shouldn't have to ask the Company because they should be addressed in their public announcements. They are basic and obvious and should not have to wait for the AGM!

I asked the following questions after the results announcement:

• Stifel is expecting 50% revenue in the pre-Elucigene business in FY2020. Did we achieve that in Q1? Was Lyn indicating that in the final sentence of his section entitled ‘Geographic exapansion’?
• What is happening in Brazil? There has been radio silence on this for over a year.
• What is the threshold i.e. % of turnover for assessing the need to announce contract wins?
• Would the Board consider lowering the threshold because this will help momentum.
• Why is Stifel predicting no revenue growth at Elucigene until FY2022? Is that your expectation?
• Who are the top 2 customers?
• What is happening with Genoma?

To which I had the following response:

Thanks for your email and insightful questions. We agree that the results were strong and were disappointed at the share price reaction. However, I am afraid we do not provide that level of information to investors as we strive to strike a balance between the AIM rules on disclosure (which are publicly available), the need to protect commercial confidentiality and certain shareholders appetite for news.

It's no wonder the share price is as bad as it is when these kinds of questions are not answered properly, leaving us confused and uncertain. They are basic, obvious questions should have been anticipated in the results announcement.

I wouldn't normally reproduce this but I am feeling very frustrated.

I think this is a really important week for YGEN and investor confidence in our ability to deliver. We need to see some good results for FY19, a strong trading update for Q120, material contract news, an update on Brazil, China and the US, progress on the Illumina product and early news on the Elucigene integration.

A tall order but us long-suffering shareholders deserve nothing less quite frankly.

Where on earth is Stifel's research note?

It's been two and a half months since their appointment so they should have produced something by now.

He bought shares on 31 May, which he can’t do within one month of the announcement of results, so I am expecting results next week, probably Wednesday or Thursday. Any wagers?!

Surely 50% would mean 16p-17p based on today’s price?

I understand TF did not want to participate in the recent placing and accepted some dilution although they were supportive of the acquisition. Still it seems cash is no longer an issue for now.

Nothing new it seems? They still emphasize no clinically significant difference in liver enzymes between Iclaprim and vancomycin so I still can’t understand what the problem is. Why does it take 30 days to send out minutes of a meeting? I am the company secretary for a large private company and I send out the minutes of board meetings the next day so I don’t forget what was said and agreed, and to give the board members a chance to review the minutes so they don’t forget what was said and agreed! Bl00dy bureaucrats!

They can’t buy if they are aware of any undisclosed price sensitive information so unlikely to be any major announcements for a little while. I would like to know when we will find out if TF is going to invest further following the recent placing.

Just watched the presentation and feel excited about the prospects especially the market entry into US and China. I didn’t like the constant use of my and I when this is a team effort and feel he is taking too much credit for the litigation settlement when this was nearly done when he arrived, but minor points. I suspect we are looking at more acquisitions and this is why we raised more money than we need for day to day requirements. When do we find out if TF will buy more shares following the recent placing?